Fundraising FoxTrust Fund — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
Nectar Allergy & Asthma is an allergy care platform offering testing, diagnosis, and treatment for food and environmental allergies, asthma, and eczema, including at-home testing kits and custom sublingual immunotherapy drops.
Digital HealthDirect to ConsumerHealthtechNew York City, US
Hersh Patel(Founder)in
Co-investorsGold House VenturesHarmony PartnersObvious VenturesMenlo Ventures
Nectar helps schools recognize and celebrate teachers through peer recognition, milestone tracking, and community appreciation features, addressing teacher burnout and retention challenges in education.
EdTechEnterprise SoftwareFuture of WorkHR TechSaaS
Co-investorsPHX VenturesBAM VenturesCharge VCFab VenturesFlying Fish VenturesGV (Google Ventures)+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.